Asia's problem isn't that people are getting old but rather the gap between how long people live and how long they stay well. Longevity becomes a dividend only when healthspan keeps pace with lifespan.

Indian hospitals and drug companies are scaling fast. The thing most likely to undo them is the thing they keep treating as a cost.

Prescriptions belong to patients, and that enduring healthcare institutions will earn trust through clinical outcomes and transparency, not captive pharmacy margins.

Asia must embed women's health into mainstream healthcare to close systemic inequities.

The healthcare industry needs a valuation framework beyond financial metrics, focusing on patient well-being.